Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Amgen, Inc.    AMGN   US0311621009

AMGEN, INC. (AMGN)

123
Delayed Quote. Delayed Nasdaq - 08/29 04:00:00 pm
139.38 USD   +0.50%
1d ago Pricing is key for new heart drugs challenging cheap generics
1d ago HK-listed Nasdaq-Amex Share Prices
5d ago NASDAQ 100 MOVERS : Vip, vrtx
SummaryQuotesChart AnalysisNewsCalendarCompanyFinancialsConsensusRevisions 

Amgen, Inc. : Amgen 1Q Profit Rises 5.2% On Broad Sales Growth

04/24/2012 | 04:40pm US/Eastern
Recommend:
0

Amgen Inc.'s (AMGN) first-quarter earnings rose 5.2% as the biopharmaceutical company reported sales growth across many of its products, helping results beat expectations.

The company has been trying to bolster its research-and-development pipeline and grow sales of its bone-building drugs to help offset declining sales of its key anti-anemia drugs, which have slumped in recent years due to safety concerns and intensifying competition. Amgen recently completed $1.16 billion acquisition of Micromet Inc. (MITI), a deal expected to strengthen its cancer-drug research pipeline.

Amgen reported a profit of $1.18 billion, or $1.48 a share, up from $1.13 billion, or $1.20 a share, a year earlier. Excluding acquisition and restructuring-related expenses and other items, earnings were up at $1.61 from $1.34. Revenue increased 9.2% to $4.05 billion.

Analysts polled by Thomson Reuters most recently projected earnings of $1.45 on revenue of $3.93 billion.

Operating margin rose to 36.4% from 34.9%.

Combined sales of Neulasta and Neupogen, which are used to ward off infections undergoing cancer treatment, rose 9% to $1.34 billion.

The company has been counting on its new bone-building drugs, Xgeva and Prolia, to boost overall sales growth. Sales of Xgeva, a drug designed to prevent bone injuries in cancer patients, were up 14% to $153 million. Sales of Prolia, for osteoporosis in women, were up 9% to $153 million.

Shares of Amgen, which affirmed its 2012 guidance, were up 1% to $69.32 in recent after-hours trading.

-By Tess Stynes, Dow Jones Newswires; 212-416-2481; Tess.Stynes@dowjones.com

Recommend :
0
React to this article
Latest news on AMGEN, INC.
1d ago Pricing is key for new heart drugs challenging cheap generics
1d ago HK-listed Nasdaq-Amex Share Prices
5d ago NASDAQ 100 MOVERS : Vip, vrtx
5d ago AMGEN : Submits Biologics License Application For Novel Investigational LDL Chol..
5d ago AMGEN : Announces Positive Top-Line Results From Phase 3 YUKAWA-2 Trial Of Evolo..
6d ago AMGEN : FDA Grants Amgen Priority Review Designation For Ivabradine For The Trea..
6d ago WESTERN DIGITAL : Timothy Leyden Retires as Western Digital CFO, Succeeded by Ol..
08/21 AMGEN : Names Elliott M. Levy, M.D., Senior Vice President, Global Development
08/21 AMGEN : Posts Positive Results of AMG 416 Study
08/21 AMGEN : Updates on Results from Kyprolis Trial
Advertisement
Chart
Duration : Period :
Amgen, Inc. Technical Analysis Chart | AMGN | US0311621009 | 4-Traders
Income Statement Evolution
Amgen, Inc. : Income Statement Evolution
More Financials
Dynamic quotes  
ON
| OFF